Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

Trial Identifier: D5161R00037
Sponsor: AstraZeneca
NCTID:: NCT05219162
Start Date: February 2022
Primary Completion Date: May 2024
Study Completion Date: May 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100210
CN Changsha, CN, 410013
CN Chengdu, CN, 610014
CN Dalian, CN, 116023
CN Foshan, CN, 528000
CN Fuzhou, CN, 350014
CN Hangzhou, CN, 310020
CN Harbin, CN, 150081
CN Hefei, CN, 230601
CN Hefei, CN, 230001
CN Linhai, CN, 317000
CN luoyang, CN, 471003
CN rizhao, CN, 276826
CN Shanghai, CN, 200032
CN Taizhou, CN, 225300
CN Tianjin, CN, 300060
CN Xiamen, CN, 361003
CN Zhengzhou, CN, 450000